Immunicum announces an update on its Phase I/II study in liver cancer

  • 08:48

Gothenburg, Sweden, March 10, 2016 – Immunicum AB (publ), striving to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced an update on the Company’s Phase I/II trial in liver cancer. The Company also announced that the first patient in the extended part of the study has been treated in the first-line setting with the cancer immune primer INTUVAX.

Read the press release here: Press release 160310 – HCC I-II uppdate